BACKGROUND: There is a need for biomarkers to screen the effectiveness of (novel) therapeutic agents for psoriasis at an early stage. OBJECTIVE: We aimed to determine which of the changes in psoriatic skin correlates best with clinical improvement 4 weeks after effective adalimumab therapy. METHODS:Twenty-two psoriatic arthritis patients were randomized to receive adalimumab or placebo. T cell numbers and markers of innate immunity were estimated in lesional and nonlesional skin biopsies at baseline and after 4 weeks of treatment. RESULTS:CD161+ andelastase+ dermal cells in lesional skin were significantly reduced upon 4 weeks of successful adalimumab treatment compared with placebo. CONCLUSION: Early improvement of psoriasis lesions during adalimumab therapy is associated with a marked reduction of infiltrated dermal CD161+ T cells and elastase+ neutrophils, suggesting that these parameters could be used as biomarkers to monitor early changes after active treatment in small proof-of-concept studies of short duration.
RCT Entities:
BACKGROUND: There is a need for biomarkers to screen the effectiveness of (novel) therapeutic agents for psoriasis at an early stage. OBJECTIVE: We aimed to determine which of the changes in psoriatic skin correlates best with clinical improvement 4 weeks after effective adalimumab therapy. METHODS: Twenty-two psoriatic arthritispatients were randomized to receive adalimumab or placebo. T cell numbers and markers of innate immunity were estimated in lesional and nonlesional skin biopsies at baseline and after 4 weeks of treatment. RESULTS:CD161+ and elastase+ dermal cells in lesional skin were significantly reduced upon 4 weeks of successful adalimumab treatment compared with placebo. CONCLUSION: Early improvement of psoriasis lesions during adalimumab therapy is associated with a marked reduction of infiltrated dermal CD161+ T cells and elastase+ neutrophils, suggesting that these parameters could be used as biomarkers to monitor early changes after active treatment in small proof-of-concept studies of short duration.
Authors: Peter Nash; Iain B McInnes; Philip J Mease; Howard Thom; Matthias Hunger; Andreas Karabis; Kunal Gandhi; Shephard Mpofu; Steffen M Jugl Journal: Rheumatol Ther Date: 2018-03-31
Authors: Janne W Bolt; Arno W van Kuijk; Marcel B M Teunissen; Dennis van der Coelen; Saïda Aarrass; Daniëlle M Gerlag; Paul P Tak; Marleen G van de Sande; Maria C Lebre; Lisa G M van Baarsen Journal: Biomedicines Date: 2022-01-29
Authors: Kathleen Weisel; Scott Berger; Kim Papp; Catherine Maari; James G Krueger; Nicola Scott; Debra Tompson; Susanne Wang; Monica Simeoni; John Bertin; Paul Peter Tak Journal: Clin Pharmacol Ther Date: 2020-07-07 Impact factor: 6.875